NeoPhore, a cancer immuno-oncology company, announced the appointment of Jeffrey Roix as Chief Executive Officer, with immediate effect.
Jeffrey brings with him over 10 years’ experience in drug discovery, having worked in academic, pharma and startup settings. He was previously Chief Operating Officer, at Cambridge-based PhoreMost Ltd, where he was responsible for launching company operations and building the company’s initial scientific and portfolio strategy. He was instrumental in setting up NeoPhore, which spun out of Phoremost and the University of Torino with financing from the CRT Pioneer Fund managed by Sixth Element Capital in November 2017.
Jeffrey has held various positions at institutions including Novartis Institute for Biomedical Research, Constellation Pharmaceuticals and Massachusetts Institute of Technology, in Cambridge MA where he specialised in cancer biology and metabolism, with an emphasis in genetics and pharmacology. Jeffrey obtained his Bachleor’s degree in biology at the Harvard Extension School.
Jeff Roix commented on his appointment: “NeoPhore is creating drugs to elicit cancer immunity in a fundamental and new way, and our target rationale has already been proven directly in cancer patients treated with immunotherapy. I am very excited to be working with our team in an innovative venture to create a next generation of cancer immunotherapy medicines.”
